Orange County’s third largest medical diagnostics and testing company is being acquired by a fast-growing Chicago-based firm using artificial intelligence for precision medicine. Aliso Viejo-based ...

On June 30, 2023, Vitality Group International, Inc. (“Vitality”) filed a notice of data breach with the Attorney General of Vermont on behalf of Ambry Genetics and REALM IDX (“Ambry”) after ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genetic and genomic testing, today announced enhancements to their portfolio of tests for the detection of genetic mutations ...

Tokyo, Japan-based Konica Minolta, a digital technology company, acquired Aliso Viejo, Calif.-based Ambry Genetics Corp., a genetic testing firm, to expand its precision medicine offerings. The Konica ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus, a leader in artificial intelligence and precision medicine, announced today that they ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of ...

Konica Minolta Inc., best known as a maker of printers and cameras, about a decade ago decided to pivot into the medical industry. Hence, in 2017, the Tokyo-based company bought Ambry Genetics, an ...

Evanston, Ill.-based NorthShore University HealthSystem’s center for personalized medicine will partner with Aliso Viejo, Calif.-based Ambry Genetics to offer 10,000 patients genetic testing. Ambry ...

Ambry Genetics, a leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., today announced the ExomeReveal™ test, a new multiomic exome sequencing test designed to improve rare disease ...

Peer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool validated with real-world patient data ...